Prestige to acquire OTC oral rehydration product Hydralyte in Australia
The acquisition, which is subject to customary closing conditions, is expected to be completed in the first quarter of fiscal 2015. The deal is expected to double the
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.
PSX1001 and PSX1050 are being developed as generic versions to GlaxoSmithKline’s pressurised metered dose inhalers (pMDI) Flixotide and Flovent, respectively. Flixotide and Flovent contain the active ingredient fluticasone
Rasuvo, which is currently under FDA review, is being developed for multiple indications, including rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis. The drug is designed to improve